Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
PEP-010 by PEP-Therapy for Metastatic Ovarian Cancer: Likelihood of Approval
PEP-010 is under clinical development by PEP-Therapy and currently in Phase I for Metastatic Ovarian Cancer. According to GlobalData, Phase...
Data Insights
PEP-010 by PEP-Therapy for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
PEP-010 is under clinical development by PEP-Therapy and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase...